Siglec-9 acts as an immune checkpoint marker on MDSCs in brucella infection
MDSCs are increased in both ABI and CBI. Siglec-9 acts as an immune checkpoint on MDSCs in patients with ineffective treatment responses. Therefore, Siglec-9 represents a potential prognostic marker for Brucella infection. Ongoing research on prognostic markers of brucellosis is promising, and further clinical studies are warranted to validate these findings.
Authors
- Fengbo Zhang (ORCID: https://orcid.org/0000-0001-5795-8672)
- Yuejie Zhu (ORCID: https://orcid.org/0000-0002-6088-8991)
- Xinxin Qi (ORCID: https://orcid.org/0000-0001-5945-6289)
- Fangfang Pu
- Jianbing Ding (ORCID: https://orcid.org/0000-0001-5506-7665)
- Huidong Shi (ORCID: https://orcid.org/0000-0003-1137-3390)
- Tingting Tian (ORCID: https://orcid.org/0000-0001-8767-091X)
- Junyu Kuang
- Rui–Xue Xu (ORCID: https://orcid.org/0000-0001-9931-201X)
- Mingzhe Li (ORCID: https://orcid.org/0000-0001-8382-0028)
- Kaiyu Shang
Institutions
- Xinjiang Medical University (CN)
- First Affiliated Hospital of Xinjiang Medical University (CN)
Publication Details
- Journal
- Frontiers in Cellular and Infection Microbiology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3389/fcimb.2025.1652116
- Primary Topic
- Brucella: diagnosis, epidemiology, treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00